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Dysfunction in effector memory has been proposed to 
contribute to autoimmunity in type 1 diabetes (T10). 
Using a unique cohort of age- and sex-matched T1 0 
patients, nonaffected siblings, and unrelated control 
children, we undertook a detailed analysis of prolifera­
tion, activation, effector responses, and apoptosis in 
reactivated CD4"'Tm cells during T -cell receptor stimu­
lation. Across cohorts, there was no difference in the 
proliferation of reactivated CD4"'Tm cells. In T1 0 patients 
and siblings, CD4"'Tm cells easily acquired the activated 
CD25+ phenotype and effectively transitioned from a cen­
tral (CD62L "'Tern) to an effector memory (CD62L -Tern) 
phenotype with an elevated cytokine "signature" com­
prising interferon (IFN)-'Y and interleukin-10 in T10 
patients and IFN-'Y in siblings. This amplified Tern phe­
notype also exhibited an exaggerated immune shut­
down with heightened sensitivity to activation-induced 
cell death and Fas-independent apoptosis. Apoptosis 
resulted in the elimination of one-half of the effector 
memory in T1 D patients and siblings compared with 
one-third of the effector memory in control subjects. 
These data suggest genetic/environment-driven immune 
alteration in T1 0 patients and siblings that manifests in 
an exaggerated CD4"'Tem response and shutdown by 
apoptosis. Further immunological studies are required 
to understand how this exaggerated CD4"'Tem response 
fits within the pathomechanisms of T1 0 and how the 
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effector memory can be modulated for disease treat­
ment and/or prevention. 
Type 1 diabetes (T1D) is an autoimmune disease that 
results from progressive T -cell-mediated destruction of 
insulin-producing [3-cells in the pancreatic islets (1). Al­
though multiple immune cell lineages participate in the 
pathogenesis of TlD, memory CD4+T cells (Tm) play 
a key inflammatory role in both inducing and maintaining 
the autoimmune response (2). The central role for CD4�m 
cells in driving disease was highlighted in a clinical trial 
showing that drug-mediated blocking of T -cell activation 
slowed !3-cell destruction (3). Disease progression could 
also be prevented in the NOD mouse model by artificially 
guiding CD4'Tm cells away from an effector memory phe­
notype toward a regulatory memory phenotype (4). These 
studies clearly point toward CD4 'Tm cells as a promising 
immune checkpoint target for T10 treatment. 
CD4 •Tm cells comprise functionally distinct central 
memory (Tern) and effector memory (Tern) subsets, and 
their relative numbers in the peripheral circulation and 
tissues vary depending on the level of antigen exposure 
(5). CD4'Tcm cells express CD62L and CCR7, home to 
lymph nodes and self-renewal. In contrast, CD4.Tem 
cells lack CD62L, migrate to tissues, and differentiate 
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into T-helper (Th)1, Th2, or Th17 lineages (6). Also con­
tained within CD41Tm cells are autoreactive cells recog­
nizing several [3-cell antigens, including GAD65, proinsulin, 
insulin, chromogranin A, and islet amyloid polypeptide (2). 
Autoreactive CD4 1Tm cells can be found in both healthy 
individuals and T1D patients (7), and their activation 
(8,9), possibly through accidental cross-reactivity (10) with 
pathogen-derived antigens (11), leads to destruction of 
J3-cells in an MHC-restricted manner. 
CD4.Tm cells re-exposed to pathogen or self-antigen 
differentiate into effector cells, producing multiple cyto­
kines that can modulate CD8•T-cell function, innate im­
munity, and antibody production by plasma cells (6). 
Alternatively, reactivated CD41Tm cells can differentiate 
into induced regulatory T (iTr) cells, which are important 
in maintaining self-tolerance through cell surface regula­
tory receptors and/or inhibitory cytokines (12). Mter the 
clearance of a pathogen, a large fraction of CD4.Tem cells 
undergo contraction (13). This contraction phase involves 
activation-induced cell death (AICD). Two distinct, but 
converging pathways mediate AICD in CD4.Tm cells, in­
cluding: 1) the extrinsic death receptor pathway (compris­
ing Fas [CD95] or tumor necrosis factor [TNF] receptor 1) 
and 2) the intrinsic mitochondrial pathway (14). In 
healthy individuals, Pas-mediated apoptosis has been sug­
gested to play a major role in the elimination of CD4 •Tern 
cells reactivated by the T -cell receptor (TCR) activation 
pathway (13). 
Enhanced effector responses, manifested by elevated 
levels of Th1 (interferon (IFN]--y and TNF-a) and Th17 
(IL-17) cytokine "signatures," drive CD4 •Tm-induced pa­
thology in both T1D patients and the NOD mouse 
(2,12,15). The intrinsic mechanisms favoring effector ver­
sus iTr lineage commitment in CD4•Tm cells of T1D 
patients (as well as in healthy subjects) remain unclear 
and controversial. Loss-of-function mutations in Fas 
and FasL genes in mice leads to T-cell-mediated autoim­
munity/lymphoproliferative pathology (16-18). Of note, 
mutations in the Fas system have been detected in 
patients with T1D (19), and collectively, these observa­
tions suggest that problems with effector immune re­
sponse shutdown perhaps caused by a defect in the 
death receptor apoptotic pathway may be a contributing 
factor for pathological autoimmunity in T1D. 
In line with this presumption, we asked in this study 
whether intrinsic differences in CD4.Tem responses and/or 
shutdown by apoptosis discriminate between T1D patients 
and healthy subjects. Using a unique cohort of age- and sex­
matched T1D patients, nonaffected siblings, and unrelated 
control children, we detail an analysis of proliferation, acti­
vation, effector responses, and apoptosis in CD4 'Tm cells 
reactivated through CD3/CD28 stimulation, which mimics 
in vivo stimulation with cognate pathogen and/or self­
derived antigen. We found that reactivated CD4.Tm cells 
from both T1D patients and siblings activated easily and 
transitioned from central memory to effector memory 
cells very efficiently, leading to an "exaggerated" Tern 
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phenotype with an elevated cytokine signature compris­
ing IFN--y and IL-10 in T1D patients and IFN--y in sib­
lings. Likewise, in both T1D patients and their siblings, we 
observed an exaggerated Tern shutdown effect with height­
ened sensitivity to AlCD, which results in elimination of 
effector memory by apoptosis. 
RESEARCH DESIGN AND METHODS 
Thirty-one children with T1D, 45 nonaffected siblings, and 
29 age- and sex-matched unrelated control children (Queens­
land Diabetes Centre, Mater Children's HospitaL Brisbane, 
QLD, Australia) were enrolled in this study (Table 1). The 
study was approved by the human research ethics committee 
of Mater Children's Hospital. Informed consent was obtained 
from parents or guardians. 
lmmunophenotype Analysis 
The following anti-human monoclonal antibodies (mAbs) 
were used: purified CD&x, HLA-DR, CD45RA, CDllc, 
CD14, CD16, CD19, CD20, and CD56 (Coulter Immuno­
tech, New South Wales, Australia); CD34, CD66c, 
CD235a, CD3-Pacific Blue, CD4-fluorescein isothiocyanate, 
Fas-fluorescein isothiocyanate, CD45RO-phycoerythrin 
(PE), CD8u-PE-Cy7, CD25-allophycocyanin (APC), CD62L­
APC, CD45-APC-H7, caspase-3-PE, and Annexin-V-PE (BD 
Bioscience, North Ryde, NSW, Australia); and FasL-PE 
(BioLegend, Karrinyup, WA, Australia). Expression of surface 
or intracellular molecules was evaluated by flow cytometry 
(BD FACS LSR II) and analyzed by FlowJo v7.6.5 software 
(Tree Star Inc.). Absolute counts of CD3'T, CD4•T, and 
CD8•T cells in the lysed whole blood of T1D patients, sib­
lings, and unrelated control children were calculated using 
multiparametric flow cytometry and Trucount beads (20). 
CD3/CD28 Stimulation Assay 
CD4 1Tm cells were purified from peripheral blood mono­
nuclear cells by negative separation, excluding CD81/ 
CD45RA'/HLA-DR1/CDllc1/CD141/CD161/CD191/CD20'/ 
CD34 1 /CD 561 /CD66c 1/CD235a 1 cells (autoMACS; Miltenyi 
Biotec, Macquarie Park, NSW, Australia). The pure negative 
fraction comprised 90-95% CD41CD45RO'Tm cells. Un­
labeled or carboxyfluorescein succinimidyl ester (CFSE)­
labeled CD4.Tm cells (1 X 105 cells/well) were maintained 
in RPMI medium supplemented with 2 mmoVL !.-glutamine, 
100 units/mL penicillin, 100 units/mL streptomycin, 
10 mmoVL HEPES (Life Technologies, Thomton, NSW, 
Australia), and 10% volume for volume autologous serum 
in the presence (reactivated cells) or absence (resting cells) 
of plate-coated anti-CD3 mAb (2 �g/rnL; eBioscience, 
Kensington, SA, Australia) and soluble anti-CD28 mAb 
(1 �g/mL; BD Bioscience) for 5 days. To address strength 
of CD3 signaling, in some experiments, plate-bound anti-CD3 
mAb was used across a range of concentrations (1, 2, 5, and 
10 �g/mL) (Supplementary Fig. 2). In cross-culture assays, 
autologous serum was replaced with allogeneic serum derived 
from siblings or unrelated control children or with FCS (Life 
Technologies). Proliferation dynamics of the reactivated 
and resting CD41Tm cells were assessed by 3H-thymidine 
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Table 1-Characteristics of research subjects 
T1D 
Number of subjects 31 
Age (years) 11.7 ::': 2.4 
Male sex 18 (58) 
Age at diagnosis (years) 8.3 ::': 3.3 
Disease duration (years) 2.0 (0.2; 8.6) 
Islet autoantibody 27 (87) 
GADA only 4 (13) 
IA-2A only 3 (10) 
GADA and IA-2A 20 (65) 
HbA1c (%) 8.3 ::': 1.4 
HbA1c (mmol/moQ 68 ::': 15.7 
C-peptide (nmoVL) 0.17 (0.1! L2) 
Subjects with high-risk 
HLA-DO haplotype ; 16 (94) 
Age-corrected BMI (z score) 0.68 ::': 0.89# 
Siblings 
45 
12.4 ::': 3. 2 
28 (62) 
1 (2) 
0(0) 
0 (0) 
1 (2)' l 
NR 
NR 
NR 
NR 
NR 
Bian and Associates 2163 
Control children P value 
29 
10.8 ::': 2.8 0.13 
17 (59) 0.92 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
WBC (1 X 103/ml) 6,382 ::': 1,551-·8 6,896 ::': 1,641-.b 8, 780 ::': 1 ,848 <0.0001a,b 
Lymphocytes (1 x 1£il/ml) 2,494 ::': 639 .. *·" 2,510 ::': 779**•b 3,403 ::': 922 o.oooaa; 0.0021 b 
Monocytes (1 x 1 £il/ml) 503 ::': 172*·" 588 ::': 169 629 ::': 204 0.041" 
Neutrophils (1 x 1£il/ml) 2,981 :!: 1,018*·" 3,399:!: 1,121 4,178 :!: 1 ,303 0.004" 
Eosinophils (1 x 103/ml) 220 (75.1,110) 259 (38 �.190) 365 (78. 1,274) 0.211 
Basophils (1 x 1 03/ml) 39.0 (5' rt04) 43 (16; 95) 49 (14 �55) 0.176 
Platelets (1 x 1 06/ml) 296 + 67 294 :!: 56 313 ::': 89 0.930 
Data are mean ::': SD, median (minimum and maximum range), and n (%). Age-corrected BMI L score (SD score) was calculated based 
on population data published by the World Health Organization. GADA, GAD antibody; IA-2A, islet antigen-2 antibody; NR, no record; 
WBC, white blood cell; ZnT8, zinc transporter 8. ' One sibling was positive for GADA, IA-2A, and ZnT8 autoantibody but did not develop 
T1D during the course of this study. i High-risk HLA-DO haplotypes were DOA1*05:01/D081*02:01 (D02) and/or DQA1*03:01/ 
DOB1*03:02 (DQ8). #There was no difference in BMI z scores between boys and girls. -p < 0.001. **P < 0.01. •p < 0.05. "Difference 
between T1 D patients and control children. bDifference between siblings and control children. 
uptake (1 J.lCi/well, PerkinElmer, Melbourne, VlC, Aus­
tralia), and kinetics of proliferation were assessed by 
CFSE dilution assay at days 1, 3, and 5 of culture. 
Apoptotic Assay 
Apoptosis was evaluated in reactivated and resting CD4'Tm 
cells at days 1, 3, and 5 of culture using Annexin-V and 
7-aminoactinomycin D (7AAD) (Sigma-Aldrich, Castle Hill, 
NSW, Australia) staining to discriminate early and late 
stages of apoptosis (Annexin-v+7AAD- and Annexin­
V7AAD+ cells). To block apoptosis, the antagonistic anti­
Pas ZB4 mAb (2.5 J.lg/mL; Merck Millipore, Bayswater, VIC, 
Australia) or the isotype control mAb (2.5 J.lg/mL IgG1 
NALE; BD Bioscience) was added at day 1 of culture. Effi­
ciency of the antagonistic anti-Fas ZB4 mAb to block Pas­
induced apoptosis was validated in Jurkat cells stimulated 
with anti-Fas CH-11 mAb (20 J.lg/mL, Merck Millipore) 
(Supplementary Fig. 3). 
Cytokine Screening 
IFN--y, IL-10, IL-4, IL-2, IL-6, TNF-a, and IL-17 were 
measured in the supematants of CD3/CD28-stimulated 
CD4+Tm cells collected at days 1, 3, and 5 of cultures 
using a cytometric bead array assay per manufacturer's 
instructions (BD Bioscience). Cytokine levels were 
determined from calculated standard curves (FCAP Ar­
ray software). 
Quantification of Apoptotic Gene Expression 
CD3/CD28-stimulated CD4'Tm cells collected at days 1 
and 5 of culture were lysed in Buffer RLT, and total RNA 
was extracted with an RNeasy Mini kit (QIAGEN, Chad­
stone Centre, VlC, Australia). cDNA was synthesized us­
ing an iScript cDNA synthesis kit and a PCR thermal 
cyder (Bio-Rad, Gladesville, NSW, Australia). The quanti­
tative PCR assay was performed on the Viia 7 Real-Time 
PCR System (Applied Biosystems, Life Technologies) to 
determine the proapoptotic BIM-L, BAD, BAX, and BAK 
and the antiapoptotic BCL2, BCLXL (BCL2Ll), and BCLW 
(BCL2L2) gene expressions. Expression of (3-actin (ACTB) 
was used as a housekeeping gene for normalization. The 
following primers were used: BIM-L: F: 5'-AYC CYC AAG 
ACA GGA GCC C-3', R: 5'-ATG GAA GCC ATT GCA CTG 
AGA-3'; BAD: F: 5'-GCA GCC ATC ATG GAG GCG CT-3', R: 
5'-CTG GGC TCC TCC CCC ATC CC-3'; BAX: F: 5'-GCC 
CTT TTG CTT CAG GGT TTC-3', R: 5' -TGA GAC ACT 
CGC TCA GCT TC-3'; BAK: F: 5'-GGC TGA TCC CGT 
CCT CCA CTG AG-3', R: 5' -CCT GGG CTA CCT GCT CCT 
CAG AAG C-3'; BCL2: F: 5'-TGG GAT GCC TTT GTG 
GAA CTA T-3', R: 5'-AGA GAC AGC CAG GAG AAA 
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TCA AAC-3' BCLXL: F: 5'-GGT CGC ATT GTG GCC ITf-
3', R: 5'-TCC TTG TCT ACG CTT TCC ACG-3'; BCLW: F: 
5'-CTG ACC CGG CTC CAC GCT GG-3', R: 5'-TCT GCC 
ACC AGA GCC CGT GT-3'; and ACTB: F: 5' -CC GTA CGC 
CAA CAC AGT GC-3', R: 5' -AT CTC CTG CTT GCT GAT 
CC-3' (GeneWorks, Hindmarsh, SA, Australia). 
Statistical Analysis 
ANOVA and x2 test were used to compare age and sex, 
respectively, between cohorts. Data within subject groups 
were compared by Mann-Whitney test and between 
groups by Kruskal-Wallis test and post hoc multiple com­
parisons. Spearman correlation test was used to analyze 
the association between clinical variables (age, age of di­
agnosis, disease duration, C-peptide levels, islet autoanti­
bodies) and continuous variables (proportion of total, 
activated, or apoptotic CD4'Tm cells). Data were analyzed 
with GraphPad Prism 6.02 software. 
RESULTS 
T1 D Is Associated With Decreased Absolute Counts of 
CD4"'Tm Cells in Peripheral Blood 
Across the three cohorts, there was no statistical differ­
ence in the percentage or absolute counts of CD4 +T cells 
defined within the total CD3' cell compartment (Fig. lA 
and B). There was also no statistical difference in the 
percentage or absolute counts of CD4' naive T cells or 
percentage of CD4 'Tm cells defined within total CD4' 
A Gated on C03' T T10 �--··------- -
... 
8 ·�, c·; .. 
<·�· 
COB 
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cells. In T1D patients, the percentage or absolute counts 
of CD4 'Tm cells did not correlate with disease duration or 
age of diagnosis (data not shown). However, there was 
a statistically significant reduction in the absolute counts 
of CD4 'Tm cells in T1D patients compared with unrelated 
control children (P = 0.024) (Fig. lB). The absolute CD4 'Tm 
cell count was also reduced in siblings, but this did not 
reach statistical significance compared with control subjects 
(P = 0.07) (Fig. lB). The lower counts of CD4.Tm cells in 
TlD patients and siblings resulted from a reduction in 
CD4.Tcm cells (Fig. lB). The alteration in CD4�m cell 
counts did not occur in isolation, being associated with 
lymphopenia and reduced numbers of CD3'T, CDB'T, and 
CD8'Tm cells in TlD patients and siblings (Table 1 and 
Supplementary Fig. 1). Neutropenia and reduced monocyte 
counts were only evident in T1D patients (Table 1). 
Increased Sensitivity of CD4"'Tm Cells to TCR 
Activation in T1 D Patients and Siblings 
Using pure ex vivo CD4.Tm cells and anti-CD3/CD28 stim­
ulation, we compared the proliferation dynamics of T cells 
from T1D patients, siblings, and unrelated control children 
in vitro (Fig. 2). There was no intergroup difference in the 
proliferation dynamics of CD4 •Tm cells by TCR stimulation 
(Fig. 2A). We also examined the kinetics of proliferation 
in the reactivated CD4'Tm cells post-CD3/CD28 stimula­
tion through CFSE labeling and multiparametric flow 
cytometry. Based on the level of CFSE expression at day 
Sib Control 
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Figure 1-CD4'T-cell counts in the peripheral blood of T1 D patients, siblings, and unrelated control children. A and 1:3: Representative dot 
plots show gating steps used to de:::ne frequency and absolute counts of the CD4"'T cells and their lineages (B) in the lysed whole-blood 
samples of T1 0 patients, siblings, and unrelated control children. Data are medians. Tn, naive T cells. •p < 0.05. 
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Figure 2-Proliferation and activation of the C04'Tm cells post-CD3/CD28 stimulation. Pure ex vivo CD4'Tm cells of T10 patients, 
siblings, and control subjects were cultured for 5 days in the presence (reactivated) or absence (resting) of anti-CD3/C028 mAb (anti­
COS mAb 2 IJ.g/ml, anti-C028 mAb 1 jig/ml). A: Proliferation assessed by 3H-thymidine uptake. B: CFSE intensity of reactivated CD4'Tm 
cells cultured for 1 day (served as the control to locate the undivided (division 0) cell position), 3 days, and 5 days. Progressive divisions (1 , 
2, 3, 4, and > 4) are apparent by even, twofold dilutions of CFSE. Computer ating used to determine the proliferation index and proportion 
of divided parent cells (median, 25 '75% quartile, and minimum and maximum range). C: Activation assessed by the expression of CD25 
(representative dot plots; bar graph with median, 25 75% quartile, and minimum and maximum range). -p < 0.01; --p < 0.0001. 
1, reactivated CD4.Tm cells underwent more than four 
divisions between day 3 and 5 of culture, with a prolifer­
ation index of 2.32, 2.27, and 2.59 and frequency of di­
vided parent cells of 47.9%, 42.0%, and 54.3% in T1D 
patients, siblings, and control subjects, respectively (Fig. 
2B). Although no statistical difference was found in the 
proliferation potential of CD4 'Tm cells, an increased per­
centage of CD4.Tm cells from TlD patients and siblings 
were activated by CD3/CD28 stimulation (Fig. 2C). The 
CD4'Tm cells from TlD patients and siblings underwent 
heightened activation regardless of the concentration of the 
plate-bound anti-CD3 mAb in the range of 1-10 J.lg/mL 
(Supplementary Fig. 2). This increase in activated 
CD4.CD25•Tm cells was not due to an increase in iTr cells 
(CD41CD251Foxp31) because iTr cells accounted for 
a similar minority ( <15% of CD4 'Tm cells) across all 
cohorts (data not shown). These results show that al­
though CD4 1Tm cells of T1D patients and siblings 
exhibited similar proliferation dynamics and kinetics com­
pared with control subjects, they were acutely more sensi­
tive to TCR-induced activation. 
Altered Functional Phenotype of CD4+-rm Cells From 
T1 D Patients and Siblings After TCR-Induced 
Activation 
Given the differences in CD4+Tm-cell postactivation status 
between cohorts, we next performed an in-depth analysis of 
cell phenotype and function (Fig. 3). After CD3/CD28 stim­
ulation, CD4'Tm cells from healthy control subjects main­
tained a CD62L1Tcm- and CD62L Tern-cell compartment 
size similar to that at day 1 of culture (Fig. 3A). This was 
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Figure 3- Functional phenotype of CD4'Tm cells after TCR-induced activation. A: Representative dot plots show gating steps used to 
de:::ile the CD62L 'Tern and CD62L Tern cells within C04'Tm cells at day 1 and 5 of culture (median; gates are set up for live CD4'Tm-cell 
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curves. FSC, forward-scattered light; SSC, side-scattered light. •p < 0.05; �p < 0.01; -p < 0.001. 
in contrast to CD4 'Tm cells of T1D patients and siblings, 
where the percentage of CD62L+Tcm cells was markedly 
lower after S days of culture (Fig. 3A). Thus, in T1D 
patients and siblings, CD4 'Tm cells effectively transi­
tioned to CD62L -Tern cells after TCR-induced activation. 
Another functional difference was related to cytokines 
secreted by CD4'Tm cells after activation (Fig. 3B). Unlike 
cells from healthy control subjects, CD4 'Tm cells from T1D 
patients significantly increased IFN--y and IL-10 production 
post-CD3/CD28 stimulation, whereas CD4 'Tm cells from 
siblings elevated IFN-")' production. Although CD3/CD28 
stimulation failed to increase the amount of secreted IL-4 
across cohorts, IL-4 production appeared to be the best 
sustained in reactivated CD4+Tm cells from T1D patients 
(Fig. 3B). Kinetic studies determined that the rise in IFN-'Y 
and IL-10 cytokine secretion occurred between days 3 and S 
of culture (data not shown). Across cohorts, there was no 
difference in the production of IL-6, TNF-o:, and IL-17 (data 
not shown). Of note, CD3/CD28 stimulation reduced the 
amount of secreted IL-2 by CD4 'Tm cells across all cohorts, 
tentatively suggesting that reactivated CD4�m cells are 
taking up the IL-2 that they produce through an autocrine 
process. Overall, the data suggest that TCR-induced stimu­
lation promotes a Tern-cell phenotype in both TlD patients 
and siblings, characterized by upregulation of IFN--y and IL-
10 in TlD patients and upregulation of IFN-'Y in siblings. 
Reactivated CD41"m Cells of T1 D Patients and 
Siblings Exhibit Increased Rates of Fas-lndependent 
Apoptosis 
Given the previous observation that CD4+Tem cells are prone 
to Pas-mediated AICD, which results in their elimination by 
apoptosis (13,21), we next examined CD4 'Tm apoptosis 
kinetics in T1D patients, siblings, and unrelated control 
children (Fig. 4). Across all cohorts, resting CD4 'Tm cells 
underwent comparable rates of apoptosis (Fig. 4A). In 
contrast, after CD3/CD28 stimulation, apoptosis rates 
of CD4 +Tm cells in T1D patients and siblings were mark­
edly elevated compared with control subjects (Fig. 4A). 
Additionally, elevated apoptosis rates of CD4+Tm cells 
in T1D patients and siblings were evident at anti-CD3 
mAb concentrations of 1-10 j.lg/mL (Supplementary Fig. 
2). Kinetic studies determined that most apoptosis oc­
curred between days 3 and S of culture (data not shown). 
Apoptotic cells were predominantly in the early stage of 
apoptosis, with a minority (<10%) in late apoptosis (data 
not shown). Apoptosis in reactivated CD4+Tm cells of 
TlD children and siblings was also associated with in­
creased frequencies of cells expressing the active form 
of caspase-3 (Fig. 4B). Interactions with serum proteins 
was excluded as a possible cause of differential CD4 'Tm 
apoptosis rates because comparable rates were observed 
regardless of the serum source (Fig. 4C). 
The death receptor (Fas) was detected on the surface of 
the majority of reactivated CD4 'Tm cells in all subject 
groups but with a higher frequency in TlD patients and 
siblings than in control subjects (Fig. SA). In contrast to 
universally high Fas expression, FasL was expressed on 
a minority of reactivated CD4.Tm cells in all subject 
groups but, again, with a higher frequency in T1D 
patients and siblings (Fig. SA). Treatment with the antag­
onistic anti-Fas ZB4 mAb, which blocks the cognate in­
teraction between Fas and FasL, reduced Fas expression 
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Figure 4-Apoptosis in reactivated CD4'Tm cells. A: For Annexin-V'7AAD'1- apoptotic cell quanticcation, gates are set up open for 
inclusion of CD4 'Tm cells of all sizes but exclusion of the cell debris (representative dot plots). The percentage of apoptotic cells within the 
reactivated and resting CD4'Tm cells at day 1 and 5 of culture (median, scatter plot) are shown. B: Caspase-3 expression within the 
reactivated (open histograms, scatter plots with median) and resting CD4 'Tm cells (closed histograms) measured at day i and 5 of culture. 
C: The percentage of apoptotic cells within the reactivated CD4'Tm cells at day 5 of culture with either autologous serum, allogeneic serum 
(from siblings or unrelated control children), or FCS (mean :! SEM). FSC, forward-scattered light; SSC, side-scattered light. •p < 0.05; 
••p < 0.01; -p < 0.001; -·p < 0.0001. 
on reactivated CD4 'Tm cells in all subject groups and 
blocked Pas-induced apoptosis in Jurkat cells but did 
not alter the levels of apoptosis of reactivated CD4' Tm 
cells in any subject group (Fig. SB and C and Supplemen­
tary Fig. 3). Increased Fas and FasL expression in reacti­
vated CD4 'Tm cells of TlD patients and siblings was 
coupled with an increase of proapoptotic BIM-L, BAD, 
BAX, and BAK transcripts compared with healthy control 
subjects (Fig. SD). Reactivated CD4 'Tm cells of TlD 
patients showed a statistically significant spike in BAD ex­
pression that separated TlD subjects from healthy control 
subjects (Fig. SD). Of note, the antiapoptotic transcripts 
BCL2, BCLXL, and BCLW remained unchanged in reacti­
vated CD4'Tm cells across all cohorts (Fig. SD). These 
data suggest that reactivated CD41'm cells ofTlD patients 
and siblings are acutely susceptible to AICD through a Pas­
independent mechanism. 
Apoptosis in Reactivated CD4+'fm Cells Is Biased 
Toward Effector Cells 
Given that CD4 'Tm cells in Till patients and siblings were 
highly susceptible to AICD, we next determined which type 
of memory cell was prone to AICD. In healthy control sub­
jects, we observed that the majority of apoptosis occurred in 
nondividing cells (Fig. 6A). In contrast, CD4+Tm cells of 
TlD patients and siblings showed consistently high levels 
of apoptosis across every cell division (Fig. 6A). Given that 
CD4'Tm cells encompass functionally distinct lineages (5), 
we subdivided the analysis of apoptosis into Tern (CD62L +) 
and Tern (CD62L ) lineages. The majority of CD4'Tm cells 
undergoing apoptosis were within the Tern lineage, which 
encompassed >80% of apoptotic cells across each cohort 
(Fig. 3B). Importantly, we observed that the apoptotic bias 
toward Tern cells was more pronounced in TlD patients and 
siblings than in control subjects, eliminating approximately 
one-half of the cells from the Tern lineage in TlD patients 
and siblings but only one-third of CD4'Tem cells in control 
subjects (Fig. 6C). In contrast to the Tern lineage, the Tern 
lineage remained largely resistant to AICD; however, the 
Tern lineage of TlD patients and siblings still showed 
greater rates of AICD compared with control subjects (Fig. 
6C). These data suggest that the cells from the Tern lineage 
are highly susceptible to AICD in TlD patients and siblings. 
DISCUSSION 
TlD is one of the most heritable common diseases, with 
high sibling relative risk and the largest concordance rate in 
monozygotic twins among the autoimmune diseases 
(22,23). Thus, if we are to understand the mechanisms of 
TlD pathophysiology and intervene with preventive or cu­
rative therapies, we must look carefully at the causes of 
immune dysfunction in patients and their at-risk siblings. 
To address this gap in knowledge, we undertook a high­
definition analysis of CD4+Tm-cell composition and function 
in an extremely well-characterized age- and sex-matched co­
hort of children comprising TlD patients, their nonaffected 
siblings, and unrelated healthy control subjects. 
We identified a distortion in the global CD4 •Tm-cell 
repertoire, with TlD patients having lower absolute 
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counts of CD4 'Tm cells compared with healthy control 
subjects. In both TlD patients and their siblings, lower 
absolute counts of CD4 'Tm cells occurred at the expense 
of CD4 'Tern cells. This reduction in CD4 'Tm cells was 
associated with reduced CD3•T-, Cos•T-, and cos•Tm­
cell counts and lymphopenia in TlD patients and their 
siblings. Given this distortion in global CD4•T-cell mem­
ory, we next asked whether a problem existed with T-cell 
proliferation, activation, and/or effector immune re­
sponse shutdown in TlD patients and siblings. Post stim­
ulation, no intergroup differences in cell proliferation was 
observed, indicating that CD4 'Tm cells of TlD patients 
and siblings were not senescent, exhausted, or defective 
in cell replication. However, we observed a difference in 
cell phenotype poststimulation, with a spike in the acti­
vated CD4.CD25.Tm cells in TlD patients and siblings 
consistent with the reported presence of activated 
CD2s•co3•T cells in TlD patients and siblings (8). 
The heightened activation potential of CD4�m cells 
was further reinforced by the observation that reactivated 
CD4 'Tm cells of TlD patients and siblings were capable of 
exaggerated effector responses through efficient switch­
ing from central memory (CD62L') to effector memory 
(CD62L -). This phenotype may provide some evolution­
ary benefit. For instance, compared with healthy control 
subjects, reactivated CD4.Tm cells of TlD patients and 
siblings can better upregulate IFN--y. IFN--y is critical for 
clearing bacteria, viruses, and cancers (24,25), and higher 
levels may result in more efficient T-cell surveillance. In­
deed, there is some evidence of a decreased risk of par­
ticular cancers in TlD patients (26,27). In line with this 
idea, we recently identified a reduced rate of infection 
with common childhood viruses in TlD patients and 
siblings compared with age-, sex-, and geographically 
matched children (J.J.M., personal communication); how­
ever, a larger cohort is needed to categorically establish 
this link. Elevated levels of IL-10 production by reacti­
vated CD4 •Tm cells in TlD patients may also be signifi­
cant given that this cytokine is known to mediate the 
destruction of �-cells in the NOD mouse (28). Sustained 
levels of the multifunctional pleiotropic cytokine IL-4 in 
reactivated CD4 'Tm cells of TlD patients is also of 
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interest given the central role of this cytokine in guiding 
the alternative fates of T-cell differentiation (29). Addi­
tionally, it appeared that reactivated CD4 •Tm cells of TlD 
patients and siblings rapidly take up secreted IL-2 
through an autocrinc process. Determining whether any 
differences in cytokine consumption among TlD patients, 
siblings, and control subjects, however, will require addi­
tional experimental approaches (e.g., quantitative PCR, 
intracellular cytokine staining). 
A striking observation in CD4'Tem cells of both TlD 
patients and siblings was a heightened sensitivity to 
AICD. Apoptosis in CD4 'Tern cells occurred through 
TCR stimulation and might be expected to result from 
Pas-mediated death rcccptor pathways (13). Although 
we observed upregulation of Pas and PasL in reactivated 
CD4 •Tm cells, there was upregulation of proapoptotic 
BIM-L, BAD, BAX, and BAK transcripts, which arc associ­
ated with the mitochondrial apoptotic pathway. Addition­
ally, we observed upregulation of the active form of 
caspase-3 shared by both apoptotic pathways. Of note, 
only in reactivated CD4 'Tm cells of TlD patients was 
a significant upregulation of the proapoptotic gene BAD 
observed, which discriminated this disease cohort from 
the other subject groups. Elevated AICD rates in CD4.Tem 
cells from both TlD patients and siblings could not be 
prevented by blocking the Fas receptor, suggesting that 
a defect may exist in the Fas death receptor pathway 
through altered lipid raft microdornains (13) or in the 
assembly of the Pas-associated death-inducing signaling 
complex (30). Alternatively, upregulation of BIM-L, BAD, 
BAX, and BAK transcripts suggests that mitochondrial 
apoptotic pathways may be mainly responsible for the 
increased rate of apoptosis in CD4'Tem cells. Finally, al­
though CD4'Tem cells of TlD patients and siblings showed 
similar suscepnbility to apoptosis, we cannot rule out that 
apoptosis could differ at the donotype level. It is possible 
that in TlD patients or siblings who go on to develop dis­
ease, autoreactive effector cells could be particularly resistant 
21 70 CD4•Tem and AICD in T1 D Patients and Siblings 
to apoptosis. Therefore, further subdividing the CD4.Tem­
cell lineage with additional phenotypic/functional markers 
and full TCR repertoire analysis would be of key interest. 
Previous investigations of CD4 'T-cell biology in TlD 
have been restricted to the comparison of patients with 
unrelated healthy control subjects (31,32). These compar­
isons likely missed critical genetic and environmental cues 
that underpin CD4+Tm-cell pathomechanisms in TlD 
patients and siblings (33). In the current study, we iden­
tified several novel aspects of CD4+Tm-cell biology com­
mon to TlD patients and siblings, including reduced 
absolute CD4.Tm and CD4.Tcm counts, exaggerated 
CD4 'Tern phenotype with an elevated IFN--y signature, 
heightened sensitivity to activation, and AICD. These fea­
tures of the CD4 ' Tm cells common to TlD patients and 
siblings associated with lymphopenia (33) but not with 
clinical variables such as age, age of disease, C-peptide 
level, and autoantibody status and are evident before 
the onset of autoimmunity and islet antibody detection. 
In conclusion, this study reveals a novel hyperactive 
phenotype of reactivated CD4 +Tm cells of TlD patients 
and their siblings. In these cells, we found that an exag­
gerated activation switch (activated CD25 receptor and 
Tern phenotype) is counterbalanced by an exaggerated 
shutdown switch (AICD). Whether an exaggerated activa­
tion switch herein induced in reactivated CD4 'Tm cells 
by polyclonal TCR stimulation also operates across other 
T-cell lineages (e.g., CD8 'T-cell lineages) as well as in re­
sponse to antigen-specific stimulation warrants further 
study. Precisely how this exaggerated activation switch 
in the CD4 +Tm-cell phenotype relates to 13-cell destruc­
tion will require a thorough immunological dissection. 
Nonetheless, these data help to further define the mech­
anisms underlying TlD pathophysiology and illuminate 
new biologically relevant surface receptors, cytokines, bio­
chemical pathways, and specific immune cell lineages for 
therapeutic targeting. 
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